Get the Stockscreener App
1.825
3.18%
-0.055
60 Degrees Pharmaceuticals Inc stock is traded at $1.825, with a volume of 21,706.
It is down -3.18% in the last 24 hours and down -52.77% over the past month.
60 Degrees Pharmaceuticals Inc operates as a specialty pharmaceutical company with the goal of using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. The firm's pipeline products under development cover development programs for COVID-19, fungal, tick-borne, and other viral diseases.
See More
Previous Close:
$1.88
Open:
$1.88
24h Volume:
21,706
Relative Volume:
0.05
Market Cap:
$2.77M
Revenue:
$502.40K
Net Income/Loss:
$-7.91M
P/E Ratio:
-0.183
EPS:
-9.972
Net Cash Flow:
$-4.32M
1W Performance:
-19.10%
1M Performance:
-52.77%
6M Performance:
-76.36%
1Y Performance:
-89.30%
1-Day Range:
$1.80
$1.90
1-Week Range:
$1.78
$2.34
52-Week Range:
$1.78
$35.99
60 Degrees Pharmaceuticals Inc Stock (SXTP) Company Profile
Name
60 Degrees Pharmaceuticals Inc
Sector
Industry
Phone
202-327-5422
Address
1025 CONNECTICUT AVENUE NW, WASHINGTON
Compare SXTP with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SXTP
60 Degrees Pharmaceuticals Inc
|
1.82 | 2.77M | 502.40K | -7.91M | -4.32M | -9.972 |
|
VRTX
Vertex Pharmaceuticals Inc
|
476.99 | 121.85B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
697.93 | 76.83B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
618.18 | 37.96B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
241.99 | 30.69B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beone Medicines Ltd Adr
|
269.08 | 29.71B | 3.32B | -860.46M | -1.04B | -8.32 |
60 Degrees Pharmaceuticals Inc Stock (SXTP) Latest News
Research Analysts Issue Forecasts for SXTP Q4 Earnings - Defense World
HC Wainwright Reaffirms “Neutral” Rating for 60 Degrees Pharmaceuticals (NASDAQ:SXTP) - Defense World
What is HC Wainwright’s Estimate for SXTP Q1 Earnings? - Defense World
60 Degrees Pharmaceuticals announces 1-for-5 reverse stock split; shares fall - MSN
A company insider recently bought 6,000 shares of 60 Degrees Pharmaceuticals Inc [SXTP]. Should You Buy? - Knox Daily
60 Degrees Pharmaceuticals and Fathom Holdings Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - ACCESS Newswire
From Malaria to New Markets: How This Pharma CEO Plans to Transform ARAKODA's Future - StockTitan
60 Degrees Pharmaceuticals, Inc. Announces 1:5 Reverse Stock Split - GlobeNewswire
60 Degrees Pharmaceuticals enacts reverse stock split By Investing.com - Investing.com Nigeria
60 Degrees Pharmaceuticals enacts reverse stock split - Investing.com India
60 Degrees Pharmaceuticals to Implement 1-for-5 Reverse Stock Split; Shares Down - Marketscreener.com
60 Degrees Pharmaceuticals, Inc. Announces 1-for-5 Reverse Stock Split to Comply with Nasdaq Listing Requirements - Nasdaq
Can This 1-for-5 Reverse Split Save 60 Degrees Pharma's Nasdaq Status? - StockTitan
60 Degrees Pharmaceuticals (SXTP) Stock Price, News & Analysis - MarketBeat
Weiss Ratings Reaffirms “Sell (E+)” Rating for 60 Degrees Pharmaceuticals (NASDAQ:SXTP) - Defense World
60 Degrees Pharmaceuticals files to sell 3.74M shares of common stock for holders - MSN
Sixty Degrees Pharmaceuticals to Ensure Continuity of Tafenoquine Supply in U.S. by Importing Limited Quantity of KODATEF® - The Manila Times
60 Degrees Gets FDA Clearance to Import Antimalarial From Australia to Ensure Supply Continuity - Marketscreener.com
Sixty Degrees Pharmaceuticals to Ensure Continuity of - GlobeNewswire
Malaria Drug Shortage Averted: FDA Green-Lights Australian Import for Critical U.S. Supply - StockTitan
60 Degrees Pharmaceuticals Inc’s latest rating changes from various analysts - Knox Daily
Bioceres Crop Solutions Corp (BIOX) Becoming More Attractive for Investors - Knox Daily
Balance Sheet Insights: 60 Degrees Pharmaceuticals Inc (SXTP)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - The Dwinnex
Insiders Give Up US$71k As 60 Degrees Pharmaceuticals Stock Drops To US$0.55 - Simply Wall St
60 Degrees Pharmaceuticals Inc [SXTP] Records 200-Day SMA of $1.8142 - Knox Daily
60 Degrees Pharmaceuticals, Inc. Closes Registered Direct Offering and Concurrent Private Placement Raising Approximately $1.075 Million - Nasdaq
Pharmaceutical Funding Alert: 60 Degrees Secures Fresh Capital Through Strategic Share Offering - StockTitan
Form 424B5 60 DEGREES PHARMACEUTICA - StreetInsider.com
How does 60 Degrees Pharmaceuticals Inc (SXTP) change from a tortoise to a hare? - SETE News
60 Degrees Pharma Announces $1.075 Million Registered Direct Offering - citybiz
60 Degrees Pharmaceuticals Secures $1.1 Mln In Registered Direct Offering - Nasdaq
60 Degrees Pharmaceuticals, Inc. Announces $1.075 Million Registered Direct Offering and Concurrent Private Placement of Common Stock and Warrants - Nasdaq
60 Degrees Pharma Announces $1.075 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules - GlobeNewswire
Pharma Stock Alert: SXTP Secures Fresh Capital Through Strategic Share Offering at $0.715 - StockTitan
Weiss Ratings Reiterates Sell (E+) Rating for 60 Degrees Pharmaceuticals (NASDAQ:SXTP) - Defense World
SXTP stock touches 52-week low at $0.7 amid market challenges - MSN
60 Degrees Pharmaceuticals, Inc. Closes Registered Direct Offering and Concurrent Private Placement Raising Approximately $1.043 Million - Nasdaq
60 Degrees Pharma Announces Closing of $1.043 Million - GlobeNewswire
60 Degrees Pharma Secures Fresh Capital: Inside the $1M Financing Deal That's Turning Heads - StockTitan
60 Degrees Pharmaceuticals announces stock and warrant sale - MSN
US Stocks Mixed; General Dynamics Earnings Top Views - Benzinga
60 Degrees Pharma Announces $1.043 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules - The Manila Times
Pharma Company's $1M Cash Injection Comes with Hidden UpsideComplete Analysis - StockTitan
US Futures Point To Cautious Start As Investors Await Fed's Rate Decision: Tesla, Microsoft, Meta Among Stocks In Focus Ahead Of Earnings - Benzinga
60 Degrees Pharmaceuticals obtains IRB approval for chronic babesiosis therapy trial - Yahoo! Voices
Why F5 Shares Are Trading Higher By 15%; Here Are 20 Stocks Moving Premarket - Benzinga
60 Degrees Pharmaceuticals Gets Investigational Review Board Approval for Babesiosis Phase 2 Study - Marketscreener.com
60 Degrees Pharmaceuticals, Inc. Announces the Approval of an Investigational Review Board Commissioned Phase II Clinical Study - Marketscreener.com
60 Degrees Pharma Announces IRB Approval of Phase II Study to Evaluate Tafenoquine for Chronic Babesiosis - GlobeNewswire
Revolutionary Tick-Borne Disease Treatment Gets Green Light: 400,000 Patients Await New Hope - StockTitan
Titan Pharma (NASDAQ:TTNP) Stock Quotes, Forecast and News Summary - Benzinga
60 Degrees Pharmaceuticals Inc Stock (SXTP) Financials Data
Revenue
Net Income
Cash Flow
EPS
60 Degrees Pharmaceuticals Inc Stock (SXTP) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| XU CHERYL | Director |
Dec 12 '24 |
Buy |
1.82 |
5,000 |
9,125 |
46,078 |
| XU CHERYL | Director |
Dec 16 '24 |
Buy |
1.45 |
2,000 |
2,900 |
54,078 |
| DOW GEOFFREY S | President and CEO |
Dec 09 '24 |
Buy |
1.27 |
35,823 |
45,563 |
94,580 |
| DOW GEOFFREY S | President and CEO |
Dec 06 '24 |
Buy |
1.20 |
20,579 |
24,672 |
58,757 |
| DOW GEOFFREY S | President and CEO |
Dec 05 '24 |
Buy |
1.11 |
17,549 |
19,520 |
38,178 |
| DOW GEOFFREY S | President and CEO |
Nov 21 '24 |
Buy |
0.91 |
3,500 |
3,195 |
20,629 |
| DOW GEOFFREY S | President and CEO |
Nov 19 '24 |
Buy |
0.90 |
2,500 |
2,248 |
16,129 |
| DOW GEOFFREY S | President and CEO |
Nov 20 '24 |
Buy |
0.92 |
1,000 |
924 |
17,129 |
| XU CHERYL | Director |
Aug 27 '24 |
Buy |
1.70 |
5,000 |
8,500 |
41,078 |
| XU CHERYL | Director |
May 16 '24 |
Option Exercise |
0.22 |
2,000 |
446 |
228,934 |
1.35%
0.90%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):